Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer (SPRAY III)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01361607 |
Recruitment Status :
Completed
First Posted : May 27, 2011
Results First Posted : April 23, 2018
Last Update Posted : April 12, 2023
|
Sponsor:
Jazz Pharmaceuticals
Collaborator:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Information provided by (Responsible Party):
Jazz Pharmaceuticals
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Triple (Participant, Care Provider, Investigator); Primary Purpose: Treatment |
Conditions |
Pain Advanced Cancer |
Interventions |
Drug: Nabiximols Drug: Placebo (GA-0034) |
Enrollment | 399 |
Participant Flow
Recruitment Details | |
Pre-assignment Details | Per the Statistical Analyses Plan, all randomized participants who received at least 1 dose of study drug were analyzed in the Intent to Treat (ITT) population as per randomized treatment group. However, if a participant randomized to placebo ever took a nabiximols dose, the participant was analyzed as nabiximols-treated in the Safety population. |
Arm/Group Title | Nabiximols | Placebo (GA-0034) |
---|---|---|
Arm/Group Description | Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day, for 5 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligram [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD. | Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day, for 5 weeks. Placebo oromucosal spray contained ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorings. |
Period Title: Overall Study | ||
Started | 200 [1] | 199 |
Received at Least 1 Dose of Study Drug | 198 | 199 |
Safety Population | 199 [2] | 198 [3] |
ITT Population | 198 | 199 [4] |
Completed | 136 | 158 |
Not Completed | 64 | 41 |
Reason Not Completed | ||
Adverse Event | 38 | 29 |
Withdrawal by Subject | 19 | 8 |
Withdrawal by Investigator | 5 | 3 |
Lost to Follow-up | 1 | 0 |
Met Withdrawal Criteria | 1 | 1 |
[1]
Two participants randomized to nabiximols did not receive any study drug
[2]
One participant randomized to nabiximols received placebo Day 22 but analyzed as nabiximols-treated
[3]
One participant randomized to placebo received nabiximols Day 1 but analyzed as nabiximols-treated
[4]
One participant randomized to placebo received nabiximols Day 1 but analyzed as placebo-treated
|
Baseline Characteristics
Arm/Group Title | Nabiximols | Placebo (GA-0034) | Total | |
---|---|---|---|---|
Arm/Group Description | Nabiximols was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day, for 5 weeks. Nabiximols oromucosal spray contained THC (27 mg/mL):CBD (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD. | Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day, for 5 weeks. Placebo oromucosal spray contained ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorings. | Total of all reporting groups | |
Overall Number of Baseline Participants | 200 | 199 | 399 | |
Baseline Analysis Population Description |
All participants who were randomized in the study.
|
|||
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
||||
Number Analyzed | 200 participants | 199 participants | 399 participants | |
60.0 (11.0) | 59.6 (11.0) | 59.8 (11.0) | ||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 200 participants | 199 participants | 399 participants | |
Female |
94 47.0%
|
102 51.3%
|
196 49.1%
|
|
Male |
106 53.0%
|
97 48.7%
|
203 50.9%
|
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Results Point of Contact
Name/Title: | Medical Enquiries |
Organization: | GW Pharmaceuticals Ltd. |
EMail: | medinfo.USA@gwpharm.com |
Responsible Party: | Jazz Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT01361607 |
Other Study ID Numbers: |
GWCA0962 2009-016065-29 ( EudraCT Number ) |
First Submitted: | May 25, 2011 |
First Posted: | May 27, 2011 |
Results First Submitted: | March 23, 2018 |
Results First Posted: | April 23, 2018 |
Last Update Posted: | April 12, 2023 |